References
- Bouroncle BA, Old JW, Jr., Vazques AG. Pathogenesis of jaundice in Hodgkin’s disease. Arch Intern Med 1962;110: 872–83.
- Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis 2008;12:203–17, x.
- Hubscher SG, Buckels JA, Elias E, McMaster P, Neuberger JM. Reversible vanishing bile duct syndrome after liver transplantation: Report of 6 cases. Transplant Proc 1991;23: 1415–6.
- Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol1988;7:193–9.
- Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: A quantitative reference standard. Hepatology 1998;28:323–31.
- Geiger H, Klepper J, Lux P, Heidland A. Biochemical assessment and clinical evaluation of a bilirubin adsorbent column (BR-350) in critically ill patients with intractable jaundice. Int J Artif Organs 1992;15:35–9.
- Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6:277–86.
- Ballonoff A, Kavanagh B, Nash R, Drabkin H, Trotter J, Costa L, et al. Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: Statistical analysis of all published cases and literature review. Acta Oncol 2008;47:962–70.
- Liangpunsakul S, Kwo P, Koukoulis GK. Hodgkin’s disease presenting as cholestatic hepatitis with prominent ductal injury. Eur J Gastroenterol Hepatol 2002;14:323–7.
- Leeuwenburgh I, Lugtenburg EP, van Buuren HR, Zondervan PE, de Man RA. Severe jaundice, due to vanishing bile duct syndrome, as presenting symptom of Hodgkin’s lymphoma, fully reversible after chemotherapy. Eur J Gastroenterol Hepatol 2008;20:145–7.
- Crosbie OM, Crown JP, Nolan NP, Murray R, Hegarty JE. Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin’s disease. Hepatology 1997; 26:5–8.
- Maeda LS, Advani RH. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol 2009;21:397–400.
- Saini KS, Azim HA, Jr., Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, et al. Rituximab in Hodgkin lymphoma: Is the target always a hit?Cancer Treat Rev 2011;37: 385–90.
- Hubscher SG, Lumley MA, Elias E. Vanishing bile duct syndrome: A possible mechanism for intrahepatic cholestasis in Hodgkin’s lymphoma. Hepatology 1993; 17:70–7.
- Strazzabosco M, Spirli C, Okolicsanyi L. Pathophysiology of the intrahepatic biliary epithelium. J Gastroenterol Hepatol 2000;15:244–53.
- Pass AK, McLin VA, Rushton JR, Kearney DL, Hastings CA, Margolin JF. Vanishing bile duct syndrome and Hodgkin disease: A case series and review of the literature. J Pediatr Hematol Oncol 2008;30:976–80.
- Rossini MS, Lorand-Metze I, Oliveira GB, Souza CA. Vanishing bile duct syndrome in Hodgkin’s disease: Case report. Sao Paulo Med J 2000;118:154–7.
- Cordoba Iturriagagoitia A, Inarrairaegui Bastarrica M, Perez de Equiza E, Zozaya Urmeneta JM, Martinez-Penuela JM, Beloqui Perez R. Ductal regeneration in vanishing bile duct syndrome in Hodgkin’s lymphoma. Gastroenterol Hepatol 2005;28:275–8.